司美格鲁肽 (诺和诺德)(Semaglutide (Novo Nordisk)) - 药物靶点：GLP-1R_在研适应症：心肌梗塞，肥胖，超重_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Semaglutide、Semaglutide (Genetical Recombination)、Semaglutide (genetical recombination) (JAN)

+ [24]

靶点

GLP-1R

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病心血管疾病+ [7]

在研适应症

非在研适应症

原研机构

在研机构

诺和诺德（中国）制药有限公司Zomagen Biosciences Ltd.

+ [6]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2017-12-05),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (中国)

登录后查看时间轴

结构/序列

Sequence Code 50953

来源: *****

关联

505

项与司美格鲁肽 (诺和诺德) 相关的临床试验

NCT05689372

/ Not yet recruitingN/A

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.

开始日期2025-03-31

申办/合作机构

Novo Nordisk A/S

NCT06639464

/ Not yet recruiting临床2期IIT

Semaglutide for the Treatment of Opioid Use Disorder: A Pilot Randomized Controlled Trial

The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.

开始日期2025-03-01

申办/合作机构

The Brigham & Women's Hospital, Inc.

NCT05646199

/ Not yet recruiting临床2/3期

The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period.
The main question it aims to answer is:
• Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS?
Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly.
The maximum duration of participation for the patients in the trial is 32 weeks.
Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

开始日期2025-03-01

申办/合作机构

The University of Hull

100 项与司美格鲁肽 (诺和诺德) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的专利（医药）

登录后查看更多信息

1,669

项与司美格鲁肽 (诺和诺德) 相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

2025-03-01·METABOLISM-CLINICAL AND EXPERIMENTAL

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

Article

作者: Fragakis, Nikolaos ; Mantzoros, Christos S ; Karakasis, Paschalis ; Patoulias, Dimitrios

BACKGROUND AND AIMS:

While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain. This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.

METHODS:

A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024. Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.

RESULTS:

Twenty-two randomized controlled trials (2258 participants) were included. GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss. However, the relative lean mass, defined as percentage change from baseline, was unaffected. Liraglutide, at 3.0 mg weekly or 1.8 mg daily, was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass. Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.

CONCLUSIONS:

Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.

2025-03-01·Endocrine Metabolic & Immune Disorders-Drug Targets

Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People

Article

作者: Wu, Hong-Yan ; Song, Cai-E ; Dai, Xue-Mei ; Wang, Yan

Objective::

The study aimed to investigate the efficacy and safety of semaglutide in weight loss in non-diabetic people.

Methods::

In this study, 84 non-diabetic people who used semaglutide to lose weight in the outpatient department of our hospital from January 1, 2022, to June 30, 2022, were enrolled and compared for changes in body weight, waist circumference, Body Mass Index (BMI), fasting blood glucose, blood pressure, pulse, and body composition (body fat ratio, visceral fat area, and skeletal muscle) before treatment and 12 weeks after the treatment to analyze the weight loss efficacy and safety.

Results::

After administering semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1.0 mg subcutaneously once a week for 12 weeks, 84 participants in this study obtained an average weight loss of 5.91 ± 3.37 kg, equivalent to 6.15 ± 4.28% of baseline body weight, and there was also a significant reduction in visceral fat area and a slight reduction in blood pressure. The most common adverse reactions included gastrointestinal reactions (nausea, vomiting, and diarrhea), which were mild and subsided within 1-2 days. No severe adverse reaction, such as hypoglycemia and hypotension, was observed.

Conclusion::

Low-dose semaglutide has been found to be effective and safe for short-term weight loss in non-diabetic people.

4,504

项与司美格鲁肽 (诺和诺德) 相关的新闻（医药）

2025-01-17

·PipelineReview

Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo. When evaluating the effects of treatment if all people adhered to treatment 1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo. When applying the treatment policy estimand 2 , people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with placebo. In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class. “We are very pleased to demonstrate 20.7% weight loss and to see that 33% of patients achieved more than 25% weight loss with semaglutide 7.2 mg, with a safety and tolerability profile comparable to semaglutide 2.4 mg,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “Results from STEP UP further strengthen the clinical profile of semaglutide for the treatment of obesity, in addition to the health benefits already established with Wegovy ® , including cardiovascular risk reduction as seen in SELECT”. The results from the second semaglutide 7.2 mg phase 3 trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next few months. Detailed results from the STEP UP trial are expected to be presented at a scientific conference in 2025. About the STEP UP trials Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy of semaglutide 7.2 mg with semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. 1,407 adults with BMI ≥30 kg/m 2 and without diabetes were included in the trial. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key secondary endpoints included number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The ongoing 72-week STEP UP T2D trial will investigate semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy ® (semaglutide 2.4 mg) Semaglutide 2.4 mg is marketed under the brand name Wegovy ® . In the EU, Wegovy ® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy ® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data showing the benefits of Wegovy ® in reducing the risk of MACE, improving HFpEF-related symptoms and physical function, as well as reducing pain related to knee osteoarthritis. In the US, Wegovy ® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in adults and paediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube . 1 Based on the trial product estimand: treatment effect if all people adhered to treatment 2 Based on the treatment policy estimand: treatment effect regardless of treatment adherence SOURCE: Novo Nordisk

临床结果临床3期

2025-01-17

·Novo Nordisk

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo. When evaluating the effects of treatment if all people adhered to treatment 1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo. When applying the treatment policy estimand 2 , people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with placebo. In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class. “We are very pleased to demonstrate 20.7% weight loss and to see that 33% of patients achieved more than 25% weight loss with semaglutide 7.2 mg, with a safety and tolerability profile comparable to semaglutide 2.4 mg,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “Results from STEP UP further strengthen the clinical profile of semaglutide for the treatment of obesity, in addition to the health benefits already established with Wegovy ® , including cardiovascular risk reduction as seen in SELECT”. The results from the second semaglutide 7.2 mg phase 3 trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next few months. Detailed results from the STEP UP trial are expected to be presented at a scientific conference in 2025. About the STEP UP trials Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy of semaglutide 7.2 mg with semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. 1,407 adults with BMI ≥30 kg/m 2 and without diabetes were included in the trial. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key secondary endpoints included number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The ongoing 72-week STEP UP T2D trial will investigate semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy ® (semaglutide 2.4 mg) Semaglutide 2.4 mg is marketed under the brand name Wegovy ® . In the EU, Wegovy ® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy ® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data showing the benefits of Wegovy ® in reducing the risk of MACE, improving HFpEF-related symptoms and physical function, as well as reducing pain related to knee osteoarthritis. In the US, Wegovy ® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in adults and paediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information Company announcement No 2 / 2025 1 Based on the trial product estimand: treatment effect if all people adhered to treatment 2 Based on the treatment policy estimand: treatment effect regardless of treatment adherence

临床结果临床3期

2025-01-17

·药时代

生物类似药集采将至！由安徽牵头

2025年1月14日，安徽省医疗保障工作会议在合肥召开。会议从7个方面对2025面全省医保工作作出部署。其中，第三项“打造效率医保”提到一个近年业内较关注的事——全国生物药品联盟集采。图片来源：安徽医保局官网得益于2015年国家食品药品监督管理总局制定发布的《生物类似药研发与评价技术指导原则（试行）》，近年来，我国生物类似药的发展逐步步入正轨，目前已有包括贝伐珠单抗、阿达木单抗、曲妥珠单抗、利妥昔单抗、英夫利西单抗、托珠单抗、地舒单抗、帕妥珠单抗等多款重磅生物类似药在国内上市，市场销售规模累计超百亿元。生物类似药被纳入集采是迟早的事，业内早有预料。 2021年1月，国务院出台《关于推动药品集中带量采购工作常态化制度化开展的意见》，文件明确提到“将带量采购常态化、制度化”。并明确指出，将探索对适应症或功能主治相似的不同通用名药品合并开展集中带量采购。文件发布后，业内专业人士指出，不考虑通用名而考虑实际的适应症或功能主治，显然是针对中成药、生物制品集采的采购原则。同时，就在此文件发布的第二天，国家医保局相关负责人在回答记者提问时也指出：“生物类似药跟化药的仿制药质量评价方式上有差别，但是它有严格的质量标准，下一步纳入集采是毫无疑义的。一些地方进行了探索，并且中选产品质量是完全可控的”。另外，此前已有不少省份已针对生物类似药集采进行小规模探索。2022年，广东等11省联盟、安徽省分别启动了对部分生物药的集采。此次安徽省医保局文件公开后，引起业内热议。信达生物股价一度下跌，业内有人猜测信达生物的此次股价正是受到了这则集采消息的影响。就在今天（1月17日），信达生物对此进行了回应，表示：目前关于集采的具体名单、规则、方式和时间都还未有更多细节，我们会跟进了解。公司现在已经有14个产品上市，其中生物类似药是3个，今年还有替妥尤单抗、玛仕度肽、匹康奇拜单抗上市，因此即使集采确认执行，对信达整体影响有限。同时，集采相应会带来销售管理费用的降低，所以对于利润的影响也有限。远期来看，2027年200亿的目标是在假设集采发生的情况下达到，不会受到影响。继半个月前第十批集采结果公布后，业内讨论的声音持续至今，主要分为两个讨论点：1）药品中标价格；2）担心集采降价后的药品质量。在17日举行的国家医保局新闻发布会上，国家医保局相关负责人表示： 1）集采省下来的钱80%用于创新药。2024年医保目录新增了38种创新药，给药企极大鼓舞。这恰恰是因为集中采购节约基金留出来的空间，2018年以来，国家组织药品带量采购累计节省医保基金4400亿元左右，其中用于谈判药使用超3600亿元。也就是说“老药”集采省下来的钱80%用于创新药，自助餐没有降档，而是保证质量的前提下老菜品批量采购，且增加了很多新菜，集采充分发挥了减负担、腾空间、促改革的动能转换作用，符合促进新质生产力发展方向。 2）国家集采走过的5个年头已经证明药品质量值得信任。“当然，也有少数群众本着‘一分价钱一分货’的朴素观点，担心降价后的药品质量。”丁一磊表示，国家集采走过的5个年头已经证明药品质量值得信任。在此，也呼吁大家擦亮眼睛，虚高的价格原来就没有形成企业利润、没有用在质量上、没有用来研发创新药，而是进入了中纪委专题片中腐败分子家中的夹墙里。希望全社会共同形成药价虚高部分坚决挤压的共识和磅礴力量。参考资料来源： 1.安徽省医保局官网、广东省药品交易中心、安徽省医药集中采购平台、国务院官网 2.其他公开资料封面图来源：123rf 往期推荐国内获批上市！首款Nectin-4 ADC又跨了一大步口服司美格鲁肽的诞生：诺和诺德的长期主义，终于帮助患者把GLP-1RA「吃」进肚子里…… 恒瑞海外NewCo的 GLP-1 公布II期喜报！会是下一个重磅吗？版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击，查看更多精彩!

生物类似药带量采购

100 项与司美格鲁肽 (诺和诺德) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10025	司美格鲁肽 (诺和诺德)	A10BJ06	DB13928

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心肌梗塞	加拿大	Novo Nordisk Canada, Inc.	2024-11-27
肥胖	美国	Novo Nordisk, Inc.	2021-06-04
超重	美国	Novo Nordisk, Inc.	2021-06-04
2型糖尿病	美国	Novo Nordisk, Inc.	2017-12-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	申请上市	中国	Novo Nordisk A/S	2024-08-26
血管疾病	临床3期	美国	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	日本	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	阿根廷	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	澳大利亚	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	巴西	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	保加利亚	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	加拿大	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	哥伦比亚	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	丹麦	Novo Nordisk A/S	2023-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05259033 (COMBINE 2, CTgov)	临床3期	2型糖尿病	683	IcoSema (IcoSema)	壓襯夢窪壓蓋衊鏇艱蓋(憲衊壓積繭夢遞窪遞觸) = 築簾積鏇選顧顧憲選鏇醖鹽蓋鏇築網夢選繭艱 (製選網襯夢觸餘壓夢蓋, 蓋憲憲夢鏇鑰獵選獵憲 ~ 獵衊鏇網顧選廠憲廠築) 更多	-	2025-01-17
				Semaglutide 1 mg (Semaglutide)	壓襯夢窪壓蓋衊鏇艱蓋(憲衊壓積繭夢遞窪遞觸) = 膚糧鬱鏇鹹構製膚遞壓醖鹽蓋鏇築網夢選繭艱 (製選網襯夢觸餘壓夢蓋, 餘鬱夢繭淵壓願蓋繭觸 ~ 顧獵壓衊鏇糧鬱襯築獵) 更多
NCT05205928 (Pubmed \| Nat Med)	临床2/3期	1型糖尿病	28	Semaglutide 1 mg	積衊鏇糧遞簾壓構遞鬱(積鹽醖蓋選鹽顧觸壓簾) = there were two episodes of recurrent euglycemic ketosis without acidosis during semaglutide use 獵簾築築築構襯鏇廠鏇 (餘築獵艱製淵獵夢鏇夢 )	积极	2025-01-10
NCT05822830 (SURMOUNT-5, Company_Website) 人工标引	临床3期	肥胖	751	Zepbound (tirzepatide)	鏇製夢獵遞構願壓範齋(糧衊製網選齋獵顧繭餘) = 衊簾鹹壓網夢繭網窪糧築齋製衊淵構糧糧窪壓 (艱構糧糧糧糧鹹蓋鏇遞 ) 更多	优效	2024-12-04
				Wegovy (semaglutide)	鏇製夢獵遞構願壓範齋(糧衊製網選齋獵顧繭餘) = 獵壓窪艱醖遞繭窪簾淵築齋製衊淵構糧糧窪壓 (艱構糧糧糧糧鹹蓋鏇遞 ) 更多
NCT04251156 (STEP7, CTgov)	临床3期	2型糖尿病 \| 肥胖	375	Semaglutide (Semaglutide 2.4 mg)	鏇艱積構醖願範鏇顧範(獵淵鑰鹽衊範醖壓夢鏇) = 鹽網壓顧顧壓選衊壓觸壓壓簾淵糧衊衊積積淵 (淵構糧壓壓網醖淵鹽醖, 衊糧製膚鹽糧淵窪願糧 ~ 衊鏇衊鏇製醖鬱壓繭顧) 更多	-	2024-11-29
				placebo+semaglutide (Placebo)	鏇艱積構醖願範鏇顧範(獵淵鑰鹽衊範醖壓夢鏇) = 顧獵願遞鏇廠餘膚鹹鬱壓壓簾淵糧衊衊積積淵 (淵構糧壓壓網醖淵鹽醖, 齋網遞遞網窪鹹醖廠鏇 ~ 築夢齋鬱簾網衊鏇選築) 更多
Pubmed 人工标引	N/A	酒精使用障碍	227,866	Semaglutide	鬱憲艱觸鏇壓網積鏇築(淵簾築範鏇範鑰鬱願淵) = A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92) of AUD hospitalization. 齋網憲襯廠壓範鏇廠獵 (廠淵廠選獵獵鑰簾製簾 ) 更多	积极	2024-11-13
				Liraglutide
NCT04560998 (STRIDE, NEWS \| Corporate Publications) 人工标引	临床3期	外周动脉疾病	-	Ozempic (semaglutide)	憲醖構憲廠齋鑰獵壓鹽(壓製遞網壓淵構顧構鬱) = 餘艱窪窪衊醖鹽鏇廠鬱遞壓構積壓繭齋襯鏇鏇 (鹽廠觸鏇築遞選襯壓選 )	积极	2024-11-07
				Placebo	憲醖構憲廠齋鑰獵壓鹽(壓製遞網壓淵構顧構鬱) = 蓋製鬱製鏇廠鬱襯餘遞遞壓構積壓繭齋襯鏇鏇 (鹽廠觸鏇築遞選襯壓選 )
NCT06489457 (Pubmed \| Diabetes Obes Metab)	临床3期	-	25	Semaglutide 1 mg/week	鏇鏇壓構壓觸獵製夢鹹(簾網遞憲餘範膚壓範獵) = 願鑰簾壓鑰鬱願糧鹹餘鑰壓築鏇窪鹽衊醖構願 (選糧鹹製憲襯醖鑰範繭, 2 ~ 5.5)	积极	2024-11-07
				Testosterone undecanoate 1000 mg/10-12 weeks	鏇鏇壓構壓觸獵製夢鹹(簾網遞憲餘範膚壓範獵) = 窪構築遞觸鑰選顧製夢鑰壓築鏇窪鹽衊醖構願 (選糧鹹製憲襯醖鑰範繭, 2 ~ 3.5)
NCT05564117 (OASIS 4, NAASO2024) 人工标引	临床3期	肥胖	-	Oral Semaglutide 25 mg	鏇鑰醖淵構顧觸衊積範(蓋膚繭鑰繭鏇蓋衊顧願) = 齋觸艱窪範窪製廠窪餘鏇鬱願願遞壓憲範淵膚 (選鹹鹽築繭糧醖遞壓醖 ) 更多	积极	2024-11-06
				Placebo	鏇鑰醖淵構顧觸衊積範(蓋膚繭鑰繭鏇蓋衊顧願) = 範鑰願廠餘憲齋憲繭繭鏇鬱願願遞壓憲範淵膚 (選鹹鹽築繭糧醖遞壓醖 ) 更多
NCT05486065 (CTgov)	临床2期	2型糖尿病 \| 超重	245	Semaglutide (Semaglutide 2.0 mg)	範鏇醖構鹽繭鏇齋淵襯(遞夢醖繭範憲餘觸積顧) = 遞鏇窪觸衊鹽遞艱鏇遞範蓋夢艱膚簾鹽鏇鬱壓 (齋窪鑰鹽遞鬱製餘淵壓, 構壓艱網選廠簾築鬱淵 ~ 積艱餘淵遞網願餘糧觸) 更多	-	2024-11-05
				Semaglutide (Semaglutide 8.0 mg)	範鏇醖構鹽繭鏇齋淵襯(遞夢醖繭範憲餘觸積顧) = 願願願壓襯醖鬱膚簾齋範蓋夢艱膚簾鹽鏇鬱壓 (齋窪鑰鹽遞鬱製餘淵壓, 夢壓鹹觸願廠窪積膚鏇 ~ 願網餘憲顧簾壓願膚夢) 更多
NCT03574597 (SELECT, PRNewswire) 人工标引	临床3期	超重 \| 肥胖	-	Semaglutide 2.4 mg	積壓衊蓋夢窪願醖鹽製(網廠構廠遞艱鬱艱鬱餘) = 繭築憲齋積廠廠製獵淵鑰齋壓餘艱簾鹽遞遞齋 (獵憲顧築鹹願齋顧鏇製 ) 更多	积极	2024-11-03
				Placebo	積壓衊蓋夢窪願醖鹽製(網廠構廠遞艱鬱艱鬱餘) = 壓積壓淵製顧顧選構築鑰齋壓餘艱簾鹽遞遞齋 (獵憲顧築鹹願齋顧鏇製 ) 更多